

# ForPatients

by Roche

Crohn's Disease Ulcerative Colitis

## A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease

**Trial Status**  
Terminated

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT03478956 2017-003649-10  
CA40192

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03478956 2017-003649-10 CA40192**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 4 Years & <= 17 Years

**Healthy Volunteers**  
No

---